Table 1.
Demographic and clinicopathologic characteristics of 24 patients diagnosed with PNENs.
| Characteristics | Histological Types | |||
|---|---|---|---|---|
| SCLC (N = 10) | LCNEC (N = 4) | AC (N = 5) | TC (N = 5) | |
| Gender | ||||
| Male | 6 (60.0%) | 1 (25.0%) | 1 (20.0%) | 3 (60.0%) |
| Female | 4 (40.0%) | 3 (75.0%) | 4 (80.0%) | 2 (40.0%) |
| Age (median, yrs) | ||||
| <56 | 3 (30.0%) | 1 (25.0%) | 4 (80.0%) | 3 (60.0%) |
| ≥56 | 7 (70.0%) | 3 (75.0%) | 1 (20.0%) | 2 (40.0%) |
| Smoke Status | ||||
| Yes | 10 (100%) | 3 (75.0%) | 1 (20.0%) | 1 (20.0%) |
| No | 0 (0.0%) | 1 (25.0%) | 4 (80.0%) | 4 (80.0%) |
| Prophylatic Radiotherapy | ||||
| Yes | 3 (30.0%) | 1 (25.0%) | 0 (0.0%) | 0 (0.0%) |
| No | 7 (70.0%) | 3 (75.0%) | 4 (100%) | 3 (100%) |
| Stage at tumor analysis | ||||
| a T Stage † | ||||
| T1 | 0 (0.0%) | 0 (0.0%) | 2 (66.7%) | 1 (33.3%) |
| T2 | 1 (16.7%) | 2 (50.0%) | 0 (0.0%) | 1 (33.3%) |
| T3 | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) |
| T4 | 5 (83.3%) | 2 (50.0%) | 0 (0.0%) | 1 (33.3%) |
| a N Stage † | ||||
| N0 | 0 (0.0%) | 1 (25.0%) | 3 (100%) | 2 (66.7%) |
| N1 | 0 (0.0%) | 1 (25.0%) | 0 (0.0%) | 1 (33.3%) |
| N2 | 2 (33.3%) | 1 (25.0%) | 0 (0.0%) | 0 (0.0%) |
| N3 | 4 (66.7%) | 1 (25.0%) | 0 (0.0%) | 0 (0.0%) |
| a M Stage † | ||||
| M0 | 4 (40.0%) | 2 (66.7%) | 3 (100%) | 3 (100%) |
| M1 | 6 (60.0%) | 1 (33.3%) | 0 (0.0%) | 0 (0.0%) |
| Pathological stage | ||||
| Early stage (I/II) | 0 (0.0%) | 0 (0.0%) | 5 (100%) | 5 (100%) |
| Advanced stage (III/IV) | 10 (100%) | 4 (100%) | 0 (0.0%) | 0 (0.0%) |
| Systemic Chemotherapy | ||||
| Yes | 8 (80.0%) | 3 (75.0%) | 2 (50.0%) | 2 (66.7%) |
| No | 2 (20.0%) | 1 (25.0%) | 2 (50.0%) | 1 (33.3%) |
| Status | ||||
| Alive | 0 (0.0%) | 1 (25.0%) | 4 (80.0%) | 5 (100%) |
| Dead | 10 (100%) | 3 (75.0%) | 1 (20.0%) | 0 (0.0%) |
| Follow-up (months) | 30 (1–168) | |||
PNENs: pulmonary neuroendocrine neoplasms; TC: typical carcinoid; AC: atypical carcinoid; LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung carcinoma. a Some cases lacked follow-up information: T stage (8); N stage (8); M stage (5); Treatment QT/RT (3). † 8th International Association for the Study of Lung Cancer [1].